VPN Plus+ ExclusiveA New Way to See an Old Disease: Updates on Canine and Feline OsteoarthritisDecember 4, 2024In this session: Kristin Kirkby Shaw, DVM, MS, PhD, DACVS, DACVSMR, reviews the latest information regarding OA prevalence in dogs and cats, provides tips for how to recognize and diagnose OA and OA pain as early as possible, discusses how to engage the entire veterinary healthcare team (including the caregiver) in management, and discusses how to develop an effective plan of care.
SPONSORED CONTENTStart Treating Canine MMVD Patients at Stage B2Learn about early treatment with pimobendan for canine Stage B2 preclinical MMVD patients. + Learn More
VPN Plus+ ExclusiveUsing NSAIDs to rein in performance horse painNovember 15, 2024OA is the leading cause of lameness in more than 60 percent of horses and is a significant concern for those managing the care of performance horses. To combat OA or soft tissue injuries, performance horses are often prescribed NSAIDs to reduce inflammation and pain.
Is CBD a better option than NSAIDs?October 2, 2023CBD has amassed evidential support and transparent quality control. Could it provide a suitable treatment choice? Certainly, more remains to be known about dosing and drug-herb interactions.
Implementing the 'OA pyramid of care'August 17, 2023As we know, a client may need to hear about your OA concerns several times before it registers, and the best time to start the conversation is when your patient is healthy, before the disease process may have begun.
Managing osteoarthritis with natural neuromodulationJune 5, 2023You may have heard a lot lately about monoclonal antibodies (mABs) for osteoarthritis (OA) pain. These agents inhibit a nerve growth factor (NGF), a molecule located in the peripheral nervous system that can contribute to neurogenic inflammation.
Canine OA injectable gets green lightMay 5, 2023Dogs afflicted with osteoarthritis (OA) pain can soon benefit from a novel treatment.
VPN Plus+ ExclusiveQuestions about anti-nerve growth factor drugsDecember 1, 2022When the guidelines first showed up, most veterinarians couldn’t even access antiNGF mAB drugs. The feline version, frunevetmab, received Food and Drug Administration (FDA) approval on January 13, 2022, but it remained unavailable to most veterinarians well into the summer. We still do not know when, or if, the canine version will receive a green light from the FDA.
Why diagnosing OA pain in cats is not easyApril 8, 2022Osteoarthritis (OA) is among the most common age-related conditions in cats.
Feline OA injectable gets green lightJanuary 28, 2022Zoetis’ Solensia treatment, containing the active ingredient frunevetmab, has been approved by the U.S. Food and Drug Administration.
How best to manage canine osteoarthritis with nutritionJuly 9, 2021Mild and moderate osteoarthritis can be managed effectively using nutritional supplements, delaying the need for treatment with NSAIDs.
